Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia

New England Journal of Medicine

Volumn 352, Issue 14, 2005, Pages 1413-1424

  Yamaguchi, Hiroki ^a   Calado, Rodrigo T ^a   Ly, Hinh ^c   Kajigaya, Sachiko ^a   Baerlocher, Gabriela M ^d   Chanock, Stephen J ^b   Lansdorp, Peter M ^d,e   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE REVERSE TRANSCRIPTASE; DNA BINDING PROTEIN; RNA; TELOMERASE; TELOMERASE RNA; TERT PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BLOOD ANALYSIS; BONE MARROW CELL; CARBOXY TERMINAL SEQUENCE; CHEEK MUCOSA; CHILD; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE DKC1; GENE EXPRESSION; GENE MUTATION; GENE NHP2; GENE NOP10; GENETIC POLYMORPHISM; GENETIC TRANSFECTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TELOMERE; CASE CONTROL STUDY; ENZYMOLOGY; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RISK FACTOR; ULTRASTRUCTURE;

ADULT; AGED; ANEMIA, APLASTIC; BONE MARROW CELLS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; RISK FACTORS; RNA; TELOMERASE; TELOMERE;

EID: 15944422499     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa042980     Document Type: Article

References (53)

1. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365-72.
2. Zeng W, Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T-cell receptor VB usage in aplastic anemia. J Clin Invest 2001;108:765-73.
3. Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenedc T-cell clones by TCR beta-CDR3 sequencing. Lancet 2004;364:355-64.
4. Young NS. Acquired aplastic anemia. Ann Intern Med 2002;136:534-46.
5. Alter BP. Inherited bone marrow failure syndromes: introduction. In: Young NS, Alter BP, eds. Aplastic anemia, acquired and inherited. Philadelphia: W.B. Saunders, 1994:271-4.
6. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 1998;19:32-8.
7. Knight SW, Heiss NS, Vulliamy TJ, et al. X-linked dyskeratosis congenita is predominantly caused by missense mutations in the DKC1 gene. Am J Hum Genet 1999;65:50-8.
8. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 1999; 402:551-5.
9. Vulliamy T, Marione A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 2001;413:432-5.
10. Theimer CA, Finger LD, Trantirek L, Feigon J. Mutations linked to dyskeratosis congenita cause changes in the structural equilibrium in telomerase RNA. Proc Natl Acad Sci U S A 2003;100:449-54.
11. Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 2003;299:259-62.
12. Vulliamy T, Marrone A, Szydlo R, Walne A, Mason PJ, Dokal I. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004;36:447-9.
13. Olovnikov AM. A theory of marginotomy: the incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 1973;41:181-90.
14. Cong YS, Wright WE, Shay JW. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002;66:407-25.
15. Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol 2000;10:399-406.
16. Harrington L. Biochemical aspects of telomerase function. Cancer Lett 2003;194: 139-54.
17. Pogacic V, Dragon F, Filipowicz W. Human H/ACA small nucleolar RNPs and telomerase share evolutionarily conserved proteins NHP2 and NOP10. Mol Cell Biol 2000; 20:9028-40.
18. Collins K, Mitchell JR. Telomerase in the human organism. Oncogene 2002;21:564-79.
19. Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997;276:561-7.
20. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood 1998;91:3582-92.
21. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PL. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001;97:895-900.
22. Vulliamy T, Marrone A, Dokal J, Mason PJ. Association between aplastic anaemia and mutations in telomerase RNA. Lancet 2002;359:2168-70.
23. Calado RT, Pintao MC, Silva WA Jr, Falcao RP, Zago MA. Aplastic anaemia and telomerase RNA mutations. Lancet 2002;360:1608.
24. Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 2003;362:1628-30.
25. Yamaguchi H, Baerlocher GM, Lansdorp PL, et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 2003; 102:916-8.
26. Kaufman DW, Kelly JP, Levy M, Shapiro S. The drug etiology of agranulocytosis and aplastic anemia. New York: Oxford University Press, 1991.
27. Packer BR, Yeager M, Staats B, et al. SNP500Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res 2004;32:D528-D532.
28. Baerlocher GM, Lansdorp PL. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry 2003;55:1-6.
29. Ly H, Blackburn EH, Parslow TG. Comprehensive structure-function analysis of the core domain of human telomerase RNA. Mol Cell Biol 2003;23:6849-56.
30. Blackburn EH. Switching and signaling at the telomere. Cell 2001;106:661-73.
31. Moriarty TJ, Huard S, Dupuis S, Autexier C. Functional multimerization of human telomerase requires an RNA interaction domain in the N terminus of the catalytic subunit. Mol Cell Biol 2002;22:1253-65.
32. Moriarty TJ, Marie-Egyptienne DT, Autexier C. Functional organization of repeat addition processivity and DNA synthesis determinants in the human telomerase multimer. Mol Cell Biol 2004;24:3720-33.
33. Ly H, Xu L, Rivera MA, Parslow TG, Blackburn EH. A role for a novel 'trans-pseudoknot' RNA-RNA interaction in the functional dimerization of human telomerase. Genes Dev 2003;17:1078-83.
34. Wenz C, Enenkel B, Amacker M, Kelleher C, Damm K, Lingner J. Human telomerase contains two cooperating telomerase RNA molecules. EMBO J 2001;20: 3526-34.
35. Beattie TL, Zhou W, Robinson MO, Harrington L. Functional multimerization of the human telomerase reverse transcriptase. Mol Cell Biol 2001;21:6151-60.
36. Arai K, Masutomi K, Khurts S, Kaneko S, Kobayashi K, Murakami S. Two independent regions of human telomerase reverse transcriptase are important for its oligomerization and telomerase activity. J Biol Chem 2002;277:8538-44.
37. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-9.
38. Armbruster BN, Banik SSR, Guo C, Smith AC, Counter CM. N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo. Mol Cell Biol 2001;21:7775-86.
39. Banik SSR, Guo C, Smith AC, et al. C-terminal regions of the human telomerase catalytic subunit essential for in vivo enzyme activity. Mol Cell Biol 2002;22:6234-46.
40. Bryan TM, Goodrich KJ, Cech TR. Telomerase RNA bound by protein motifs specific to telomerase reverse transcriptase. Mol Cell 2000;6:493-9.
41. Ly H, Calado RT, Allard P, et al. Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood 2005;105:2332-9.
42. Marrone A, Stevens D, Vulliamy T, Dokal I, Mason PJ. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood 2004;104:3936-42.
43. Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 2000;10:1459-62. [Erratum, Curr Biol 2001;11:907.]
44. Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol 2000;10:1459-62. [Erratum, Curr Biol 2001;11:907.]
45. Zhang A, Zheng C, Hou M, et al. Deletion of the telomerase reverse transcriptase gene and haploinsufficiency of telomere maintenance in Cri du chat syndrome. Am J Hum Genet 2003;72:940-8.
46. Kiss AM, Jady BE, Bertrand E, Kiss T. Human box H/ACA pseudouridylation guide RNA machinery. Mol Cell Biol 2004; 24:5797-807.
47. Lee HW, Blasco MA, Gottlieb GJ, Horner JW II, Greider CW, DePinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature 1998;392:559-74.
48. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34.
49. Rudolph KL, Chang S, Lee HW, et al. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 1999; 96:701-12.
50. Maciejewski JP, Follmann D, Nakamura R, et al. Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome. Blood 2001;98:3513-9.
51. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
52. Dufour C, Capasso M, Svahn J, et al. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anemia in Caucasian population. Br J Haematol 2004;126:682-5.
53. Peng J, Liu C, Zhu K, et al. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum Immunol 2003;64:896-901.